ro 03-7410 has been researched along with fluoxetine in 1 studies
*Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. [MeSH]
*Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants. [MeSH]
Studies (ro 03-7410) | Trials (ro 03-7410) | Recent Studies (post-2010) (ro 03-7410) | Studies (fluoxetine) | Trials (fluoxetine) | Recent Studies (post-2010) (fluoxetine) |
---|---|---|---|---|---|
5 | 1 | 1 | 10,100 | 1,663 | 3,263 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Margolis, JM; Obach, RS | 1 |
1 other study(ies) available for ro 03-7410 and fluoxetine
Article | Year |
---|---|
Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions.
Topics: Benzylamines; Bridged Bicyclo Compounds, Heterocyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Imipramine; In Vitro Techniques; Microsomes; Phospholipids; Protein Binding; Quinidine | 2003 |